Welcome to our dedicated page for Biofrontera SEC filings (Ticker: BFRIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biofrontera Inc. warrants (BFRIW) SEC filings page provides direct access to the regulatory documents that describe both the warrant security and the broader Biofrontera Inc. business. Company filings identify BFRIW as warrants to purchase common stock of Biofrontera Inc., whose common shares trade on The Nasdaq Capital Market under the symbol BFRI. These documents outline listing details, capital structure changes, and transactions relevant to holders of the warrants and the underlying equity.
Through registration statements such as the S‑1/A, investors can review descriptions of Biofrontera’s operations, including its focus on photodynamic therapy in dermatology, its principal licensed product Ameluz® used with RhodoLED® lamps for actinic keratoses, and its status as an emerging growth and smaller reporting company. Forms 8‑K capture material events such as financings with Series C and Series D Convertible Preferred Stock, the strategic transaction with Biofrontera AG to acquire all U.S. rights to Ameluz and RhodoLED, and stockholder approvals for reverse stock split authority and preferred stock conversions.
Proxy materials (such as the DEF 14A for a special meeting) detail stockholder proposals related to reverse splits, increases in authorized common stock, and approvals required under Nasdaq rules for preferred stock conversions. Other 8‑K filings report on matters such as financial results, appointment of key officers, and submission of matters to a vote of security holders.
On this page, users can follow Biofrontera’s 10‑K and 10‑Q reports (when filed), 8‑Ks, registration statements, and proxy statements as they become available from EDGAR. Stock Titan’s platform adds AI-powered summaries to help explain the main points of lengthy filings, highlight changes in capital structure that may affect BFRIW, and clarify how clinical, regulatory, and transactional disclosures relate to Biofrontera’s dermatology-focused business.
Biofrontera Inc. director Kevin Daniel Weber reported receiving an employee stock option grant to acquire 20,000 shares of the company’s stock. The option carries an exercise price of $0.00 per share and represents a new award, bringing his total directly held derivative securities from this grant to 20,000 options.
According to the disclosure, the option vests in twelve equal monthly installments beginning on April 4, 2026, meaning the right to exercise will phase in over one year. The filing notes that other options with different terms are not included in this reported transaction.
Biofrontera Inc. CEO and Chairman Hermann Luebbert reported several equity awards and an option-related share conversion. On March 4, 2026, he received 125,000 restricted stock units and an employee stock option for 125,000 shares, both at a price of $0.00 per unit or option. The restricted stock units vest in two equal yearly installments beginning on March 4, 2027, and may be settled in shares, cash, or a combination within 60 days of each vesting date. The option vests in two equal installments on September 4, 2026 and March 4, 2027. On March 5, 2026, 137,500 restricted stock units were exercised or converted into 137,500 shares of common stock at $0.00 per share, bringing his directly held common stock to 290,211 shares after the transaction.
Biofrontera Inc. Chief Financial Officer Eugene Frederick Leffler reported equity compensation activity, mainly awards and a derivative conversion. On March 4, 2026, he received 62,500 restricted stock units and 62,500 employee stock options, both granted for no cash consideration.
On March 5, 2026, 87,500 restricted stock units were converted into 87,500 shares of common stock at a price of $0.00 per share, leaving him with 175,000 common shares held directly after the transaction.
Lanckriet Heikki reported acquisition or exercise transactions in this Form 4 filing.
Biofrontera Inc. director Heikki Lanckriet received a grant of employee stock options covering 20,000 shares on March 4, 2026. These options were awarded at a stated price of $0.0000 per share and represent a new direct derivative holding of 20,000 options.
The option grant vests in twelve equal monthly installments, beginning on April 4, 2026, spreading the benefit to the director over one year. The disclosure notes that options with different terms are not included in this reported amount.
Hoffman Beth J. reported acquisition or exercise transactions in this Form 4 filing.
Biofrontera Inc. director Beth J. Hoffman reported receiving an award of 20,000 employee stock options on March 4, 2026. The options were granted at a reported price of $0.0000 per share. They vest in twelve equal monthly installments beginning on April 4, 2026. After this grant, she holds 20,000 options directly.
Biofrontera Inc. reported that Chief Commercial Officer George Patrick Jones acquired new equity-based compensation. He received 50,000 restricted stock units, each representing a contingent right to one share of BFRI common stock awarded for no consideration.
He also received an option for 50,000 shares with a grant price of $0.00. The option vests in two equal installments on September 4, 2026 and March 4, 2027. The restricted stock units vest in two equal yearly installments beginning March 4, 2027, and each vested unit will be settled in shares, cash, or a combination within 60 days at the company’s discretion.
Biofrontera Inc. director John J. Borer III received an employee stock option grant on March 4, 2026. The award covers options to purchase 20,000 shares, reported at a price of $0.00 per share as a derivative security grant. According to the terms, the option vests in twelve equal monthly installments beginning on April 4, 2026, so the director earns the right to exercise portions of the option gradually over one year.
Biofrontera Inc. reports a significant development in its patent dispute with Sun Pharmaceutical Industries. On February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision finding all challenged claims of Sun’s U.S. Patent No. 11,697,028 unpatentable.
Sun may still request rehearing, seek review by the Director of the U.S. Patent and Trademark Office, or appeal to the U.S. Court of Appeals for the Federal Circuit, so the outcome is not yet final. The company notes that the impact of this decision on ongoing proceedings in the U.S. District Court for the District of Massachusetts and the International Trade Commission cannot be determined at this time.
Rosalind Master Fund L.P. and related parties report beneficial ownership of approximately 9.9% of Biofrontera Inc. common shares. The stake is reported on a passive basis and is calculated using 11,648,323 common shares outstanding as of November 10, 2025.
Rosalind Master Fund L.P. may be deemed to beneficially own 1,140,764 common shares, with additional 15,048,017 shares issuable from preferred shares and convertible debt that are subject to a 9.99% ownership blocker and therefore not currently exercisable. Rosalind Advisors, Inc. acts as investment adviser, and portfolio managers Steven Salamon and Gilad Aharon may be deemed beneficial owners but disclaim beneficial ownership.
Biofrontera Inc. reported positive, statistically significant Phase 3 results for Ameluz® photodynamic therapy (PDT) to treat mild to moderate actinic keratoses on the extremities, neck, and trunk using its RhodoLED® platform.
Ameluz® PDT achieved complete clearance in 45.6% of patients in the Full Analysis Set, versus 16.7% with vehicle PDT (p < 0.0003), and 53.2% versus 22.2% in the Per Protocol Set (p < 0.001). Lesion clearance reached 73.1% in the Full Analysis Set and 80.3% in the Per Protocol Set. Investigators rated cosmetic outcomes as good or very good in 75.2% of patients, and 86.3% indicated they would choose PDT again. Based on these data, Biofrontera plans to submit a supplemental New Drug Application to the FDA in the third quarter of 2026 for a potential label expansion beyond the face and scalp.